Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Robert J. Kreitman(National Cancer Institute), Barbara Dreta(University Hospital Centre Zagreb), Gimena dos Santos(Northwestern University), D. Donaldson(University of St Andrews), Evangelia Minga(Centre for Research and Technology Hellas), Christos Demosthenous(Mayo Clinic), Ιoannis Kotsianidis(Democritus University of Thrace), Yair Herishanu(Tel Aviv University), Bonnie Kho(Pamela Youde Nethersole Eastern Hospital), Mehreen Ali Khan(National Institute Of Blood Disease and Bone Marrow Transplantation), Rosa Collado(Hospital General Universitario De Valencia), Rocío García‐Serra(Hospital General Universitario De Valencia), Marcos Daniel de Deus Santos(Universidade Federal do Espírito Santo), Alessandro Gozzetti(University of Siena), Lydia Scarfò(IRCCS Ospedale San Raffaele), Shaimaa El‐Ashwah(Mansoura University), Ramona Cassin(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alberto Fresa(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Dimou(National and Kapodistrian University of Athens), Maya Koren‐Michowitz(Jacksonville University), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Isabel González-Gascón-y-Marín(University Hospital Centre Zagreb), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Alicia Enrico(Hospital Italiano La Plata), Eleftheria Hatzimichael(Thomas Jefferson University), Zadie Davis(Royal Bournemouth Hospital), Michalis Iskas(G. Papanikolaou General Hospital), Sean Harrop(The University of Melbourne), Volkan Karakuş(Antalya Eğitim ve Araştırma Hastanesi), Arnon P. Kater(Amsterdam University Medical Centers), Jana Kotašková(Central European Institute of Technology), Rainer Claus(University of Augsburg), Valerio Guarente(University of Perugia), Sofia Chatzileontiadou(AHEPA University Hospital), Thomas Longval(Centre Hospitalier de Versailles), Elisabetta Albi(University of Perugia), Thérèse Aurran(Institut Paoli-Calmettes), Ozren Jakšić(University of Zagreb), Luca Inchiappa(Institut Paoli-Calmettes), Dimitra Chammou(Centre for Research and Technology Hellas), Amy Christian(Tel Aviv University), Francesca Bacchiarri(University of Siena), Maria Efstathopoulou(Mansoura University), Elżbieta Kalicińska(The University of Melbourne), Iliana Konstantinou(National and Kapodistrian University of Athens), Susanne R. Janssen(Tel Aviv University), Sara Galimberti(University of Pisa), Anne Calleja(Institut Paoli-Calmettes), Georgios Karakatsoulis(University of Ioannina)
Cited by 1
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630